Skip to main content
SpringerLink
Log in

Cutaneous Outcome Measures of Adult Dermatomyositis

  • Living reference work entry
  • Latest version View entry history
  • First Online:
Cutaneous Biometrics

  • 7 Accesses

Abstract

Dermatomyositis is an autoimmune skin disease marked by inflammation of the skin and muscle. The skin manifestations significantly impact quality of life and are difficult to treat. Therefore, clinical trials for effective therapies to treat the skin involvement in dermatomyositis are critical. There are many validated outcome measures that allow physicians to objectively evaluate response to treatment in clinical trials and in the clinic. This chapter reviews the following popular tools to assess skin severity in dermatomyositis: the Cutaneous Dermatomyositis Disease Area and Severity Index, the Physician Global Assessment, and the Cutaneous Assessment Tool-Binary Method. Based on validation studies outlined in this chapter, it appears that the Cutaneous Dermatomyositis Disease Area and Severity Index demonstrates superiority over the other tools and is a useful outcome measure for dermatomyositis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Aggarwal R, Charles-Schoeman C, Schessl J, et al. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med. 2022;387(14):1264–1278.

    Google Scholar 

  • Ahmed S, Chakka S, Concha J, Krain R, Feng R, Werth VP. Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis. Br J Dermatol. 2020;182(4):949–954.

    Google Scholar 

  • Anyanwu CO, Fiorentino DF, Chung L, Dzuong C, Wang Y, Okawa J, et al. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol. 2015;173(4):969–74.

    Google Scholar 

  • Anyanwu CO, Chansky PB, Feng R, Carr K, Okawa J, Werth VP. The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy. Int J Women’s Derm. 2017;3(4):189–94.

    Article  CAS  Google Scholar 

  • Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol. 2006;24(5):363–73.

    Article  PubMed  Google Scholar 

  • Chansky PB, Olazagasti JM, Feng R, Werth VP. Cutaneous dermatomyositis disease course followed over time using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI). J Am Acad Dermatol. 2017;79(3):464–469.

    Google Scholar 

  • Dan J, Afarideh M, Sprow G, et al. Preliminary definition of cutaneous flare in dermatomyositis: A retrospective review. J Am Acad Dermatol. 2023;88(1):190–191

    Google Scholar 

  • Dan J, Sprow G, Concha J, et al. A comparison of the efficacy of Skindex-16 and Skindex-29 in dermatomyositis. Br J Dermatol. 2023;189(2):227–228.

    Google Scholar 

  • Gaines E, Werth VP. Development of outcome measures for autoimmune dermatoses. Arch Dermatol Res. 2008;300(1):3–9.

    Article  CAS  PubMed  Google Scholar 

  • Goreshi R, Okawa J, Rose M, Feng R, Lee LA, Hansen CB, et al. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dermatol. 2012;132(4):1117–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huard C, Gulla SV, Bennett DV, Coyle AJ, Vleugels RA, Greenberg SA. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon beta in dermatomyositis. Br J Dermatol. 2017;176(5):1224–30.

    Article  CAS  PubMed  Google Scholar 

  • Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, et al. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum. 2008a;59(2):214–21.

    Article  PubMed  Google Scholar 

  • Huber AM, Lachenbruch PA, Dugan EM, Miller FW, Rider LG. Juvenile Dermatomyositis Disease Activity Collaborative Study G. Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats. Arthritis Rheum. 2008b;59(3):352–6.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hundley JL, Carroll CL, Lang W, Snively B, Yosipovitch G, Feldman SR, et al. Cutaneous symptoms of dermatomyositis significantly impact patients’ quality of life. J Am Acad Dermatol. 2006;54(2):217–20.

    Article  PubMed  Google Scholar 

  • Klein RQ, Bangert CA, Costner M, Connolly MK, Tanikawa A, Okawa J, et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol. 2008;159(4):887–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kleitsch J, Weiner JD, Pandya R, Concha JS, Lim D, Werth VP. The physical and emotional impact of cutaneous dermatomyositis: a qualitative study [published online ahead of print, 2023 Apr 16]. Arch Dermatol Res. 2023;10.1007/s00403-023-02625-2.

    Google Scholar 

  • Lim D, Fiorentino D, Werth V. Current concepts and advances in dermatomyositis: a dermatological perspective. Clin Exp Rheumatol. 2023;41(2):359-369.

    Google Scholar 

  • Pandya R, Dan J, Kleitsch J, Lim D, White B, Werth V. A Revised Outcome Measure for Dermatomyositis Clinical Trials: The Dermatomyositis Outcomes for Muscle and Skin (DMOMS) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9).

    Google Scholar 

  • Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol. 2003;30(3):603–17.

    PubMed  Google Scholar 

  • Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S118–57.

    PubMed  Google Scholar 

  • Robinson ES, Feng R, Okawa J, Werth VP. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. Br J Dermatol. 2015;172(1):169–74.

    Article  CAS  PubMed  Google Scholar 

  • Singer AJ, Thode HC Jr, Hollander JE. Research fundamentals: selection and development of clinical outcome measures. Acad Emerg Med. 2000;7(4):397–401.

    Article  CAS  PubMed  Google Scholar 

  • Tiao J, Feng R, Berger EM, Brandsema JF, Coughlin CC, Khan N, et al. Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. Br J Dermatol. 2017a;177(4):1086–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tiao J, Feng R, Bird S, Choi JK, Dunham J, George M, et al. The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists. Br J Dermatol. 2017b;176(2):423–30.

    Article  CAS  PubMed  Google Scholar 

  • Werth VP, Hejazi E, Pena SM, et al. Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial. J Invest Dermatol. 2022;142(10):2651-2659.e1.

    Google Scholar 

  • Wolstencroft PW, Chung L, Li S, Casciola-Rosen L, Fiorentino DF. Factors associated with clinical remission of skin disease in dermatomyositis. JAMA Dermatol. 2018;154(1):44–51.

    Article  PubMed  Google Scholar 

  • Yassaee M, Fiorentino D, Okawa J, Taylor L, Coley C, Troxel AB, et al. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br J Dermatol. 2010;162(3):669–73.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA

    Rebecca G. Gaffney & Victoria P. Werth

  2. Department of Dermatology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA

    Victoria P. Werth

  3. Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA

    Rebecca G. Gaffney

Authors
  1. Rebecca G. Gaffney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victoria P. Werth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Victoria P. Werth .

Editor information

Editors and Affiliations

  1. Dept Dermatology, 110 Surge Bldg, UCSF School of Medicine Dept Dermatology, 110 Surge Bldg, San Francisco, CA, USA

    Howard Maibach

  2. Department of Dermatology, University of California, San Francisco Department of Dermatology, San Francisco, CA, USA

    Nily Osman

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Gaffney, R.G., Werth, V.P. (2024). Cutaneous Outcome Measures of Adult Dermatomyositis. In: Maibach, H., Osman, N. (eds) Cutaneous Biometrics. Springer, Cham. https://doi.org/10.1007/978-3-319-56591-0_30-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56591-0_30-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56591-0

  • Online ISBN: 978-3-319-56591-0

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Cutaneous Outcome Measures of Adult Dermatomyositis
    Published:
    29 January 2024

    DOI: https://doi.org/10.1007/978-3-319-56591-0_30-2

  2. Original

    Cutaneous Outcome Measures of Adult Dermatomyositis
    Published:
    30 November 2018

    DOI: https://doi.org/10.1007/978-3-319-56591-0_30-1

Search

Navigation